A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
Open accessPublished version of a preprint
Abstract
Purpose: Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclinical models, inducing S-phase arrest and apoptosis in TP53 wild-type and mutant tumors. This study evaluated the safety and tolerability of serdemetan, determined the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose. Patients and Methods: Patients (71) with refractory solid tumors were allocated to dose-escalating cohorts (3+3 patients each) and received oral serdemetan once daily in 21-day cycles to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT). Plasma was collected for pharmacokinetic analyses. Paired baseline and on-treatment skin and tumor biopsies were done; blood samples were collected for pharmacodynamic analyses, including p53 and macrophage inhibitory cytokine-1 induction. Results: The MTD of serdemetan was determined to be 350 mg once daily. During this study, grade 3 QTc prolongation was the most common DLT and nausea (66.2%) was the most frequent treatment-emergent adverse event. Serdemetan was rapidly absorbed after oral administration and exhibited dose-proportional pharmacokinetics. At steady state, mean maximum plasma concentration (Cmax) was 2,330 ng/mL and mean area under plasma concentration curve (AUC0–24h) was 43.0 μg.h/mL, with serdemetan 300 mg/d. There was a dose- and exposure-dependent p53 induction. One patient with breast cancer showed a partial response; 22 (38.6%) patients had stable disease. Conclusions: Serdemetan treatment was associated with p53 induction in both tumor and surrogate tissue pharmacodynamic studies and modest clinical activity. Although serdemetan was well tolerated with dose-proportional pharmacokinetics, exposure-related QTc liability was observed. Clin Cancer Res; 17(19); 6313–21. ©2011 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More preclinical studies reported that JNJ-26854165 increased p53 levels in U87 glioblastoma grafts, accompanied by apoptotic stimulation.
“More preclinical studies reported that JNJ-26854165 increased p53 levels in U87 glioblastoma grafts, accompanied by apoptotic stimulation.373–376”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [375]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569 · see citing works
Phase I Clinical Trial Design in Cancer Drug Development
Eisenhauer, E. A., O'Dwyer, P. J., Christian, M. C., & Humphrey, J. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.684 · Cited by 239 · see citing works
Second Berkeley Symposium on Mathematical Statistics and Probability
Neyman, J. (1949) · Cited by 154 · see citing works
National Cancer Institute-Common Toxicity Criteria
下山正徳 (1999) · 癌と化学療法 · Cited by 132 · see citing works
Functional Mechanisms for Human Tumor Suppressors
Sun, W., & Yang, J. P. (2010) · Journal of Cancer · doi:10.7150/jca.1.136 · Cited by 89 · see citing works
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78 · see citing works
Graham, M. A., & Workman, P. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058203 · Cited by 53 · see citing works
Mouse to man: statistical problems in bringing a drug to clinical trial
Schneiderman, M. A. (1967) · Project Euclid (Cornell University) · Cited by 35 · see citing works
Innovations in phase 1 trial design: where do we go next?
Collins, J. M. (2000) · PubMed · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 11 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada‐Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,601 · see citing works
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744 · see citing works
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 611 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & ller, M. M. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 294 · see citing works
Role of p53 in breast cancer progression: An insight into p53 targeted therapy
Marvalim, C., Datta, A., & Lee, S. C. (2023) · Theranostics · doi:10.7150/thno.81847 · Cited by 243 · see citing works
Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Jandial, D., Blair, C., Zhang, S., Krill, L. S., Zhang, Y., & Zi, X. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140122160515 · Cited by 132 · see citing works
Shen, H., Zhang, J., Wang, C., Jain, P., Xiong, M., Shi, X., Lei, Y., Chen, S., Yin, Q., Thistlethwaite, P. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048191 · Cited by 127 · see citing works
Self-citationEmerging therapies targeting the ubiquitin proteasome system in cancer
Weathington, N. M., & Mallampalli, R. K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71602 · Cited by 124 · see citing works
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 101 · see citing works
Manji, A., Braña, I., Amir, E., TOMLINSON, G. A., Tannock, I. F., Bedard, P. L., Oza, A. M., Siu, L. L., & Razak, A. R. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4957 · Cited by 97 · see citing works
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 80 · see citing works
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79 · see citing works
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65 · see citing works
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 65 · see citing works
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R. G., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 64 · see citing works
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 62 · see citing works
Self-citationAscierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 52 · see citing works
Sampson, V. B., Gorlick, R. G., Kamara, D. F., & Kolb, E. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00132 · Cited by 51 · see citing works
Wu, J., Kumar, S., Wang, F., Wang, H., Chen, L., Arsenault, P., Mattern, M. R., & Weinstock, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00498 · Cited by 45 · see citing works
Role of E3 ubiquitin ligases in insulin resistance
Yang, X., Xiang, D., & Yang, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12677 · Cited by 43 · see citing works
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40 · see citing works
Sosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 38 · see citing works
Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites
Douglass, A. N., Kain, H. S., Abdullahi, M., Arang, N., Austin, L. S., Mikolajczak, S. A., Billman, Z. P., Hume, J. C. C., Murphy, S. C., Kappe, S. H. I., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.18 · Cited by 31 · see citing works
Resistance acquisition to MDM2 inhibitors
Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140035 · Cited by 30 · see citing works
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 28 · see citing works
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 27 · see citing works
Jones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204958 · Cited by 26 · see citing works
The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer
Matos, B., Howl, J., Jerónimo, C., & Fardilha, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105145 · Cited by 26 · see citing works
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1–MDM2–p53 Pathway
Qin, J., Wang, W., & Zhang, R. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.005 · Cited by 22 · see citing works
Locatelli, M., Criscitiello, C., Espósito, A., Minchella, I., Goldhirsch, A., Cipolla, C. M., & Curigliano, G. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0325-x · Cited by 20 · see citing works
Hu, W., Wang, G., Chen, Y., Yarmus, L. B., Liu, B., & Wan, Y. (2020) · Aging · doi:10.18632/aging.103775 · Cited by 19 · see citing works
The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Kumar, S., Mattern, M. R., Goldberg, M. S., & Butt, T. R. (2023) · NeuroMolecular Medicine · doi:10.1007/s12017-023-08738-1 · Cited by 16 · see citing works
Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach
Stintzing, S., & Lenz, H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3175 · Cited by 16 · see citing works
Tatsuda, D., Momose, I., Someno, T., Sawa, R., Kubota, Y., Iijima, M., Kunisada, T., Watanabe, T., Shibasaki, M., & Nomoto, A. (2015) · Journal of Natural Products · doi:10.1021/np500581m · Cited by 16 · see citing works
Ye, Q., Raese, R. A., Luo, D., Feng, J., Xin, W., Dong, C., Qian, Y. R., & Guo, N. L. (2023) · Cells · doi:10.3390/cells12141917 · Cited by 15 · see citing works
Ascierto, P. A., Grimaldi, A. M., Anderson, A. C., Bifulco, C. B., Cochran, A. J., Garbe, C., Eggermont, A. M. M., Faries, M. B., Ferrone, S., Gershenwald, J. E., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0277-z · Cited by 15 · see citing works
Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes
Lehman, J. A., Hauck, P. M., Gendron, J. M., Batuello, C. N., Eitel, J. A., Albig, A. R., Kadakia, M., & Mayo, L. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074741 · Cited by 14 · see citing works
You, L., Liu, H., Huang, J., Xie, W., Wei, J., Ye, X., & Qian, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13951 · Cited by 11 · see citing works
Ling, H. Y., Xiao, S., Lei, Y., Zhou, Y., Tan, J., Chen, X., Ma, D., Liang, C., Liu, Q., Liu, W., et al. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110497 · Cited by 9 · see citing works
Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy
Wustrow, D. J., Zhou, H.-J., & Rolfe, M. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00014-4 · Cited by 9 · see citing works
New targeted approaches against the ubiquitin–proteasome system in gastrointestinal malignancies
Grande, E., Earl, J., Fuentes, R., & Carrato, A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.26 · Cited by 7 · see citing works
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7 · see citing works
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer
Grazia, G., Conti, C., Nucera, S., Stella, S., Massimino, M., Giuliano, M., Schettini, F., Vigneri, P. G., & Martorana, F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104834 · Cited by 6 · see citing works
Li, A., Huang, H.-T., Huang, H., & Juan, H. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.007 · Cited by 6 · see citing works
Braña, I., Zamora, E., Oristrell, G., & Tabernero, J. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_14 · Cited by 6 · see citing works
Self-citationPrognostic model based on tumor stemness genes for triple-negative breast cancer
Ouyang, M., Gui, Y., Li, N., & Zhao, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-81503-x · Cited by 4 · see citing works
Gunasegaran, B., Neilsen, P. M., & Smid, S. D. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104908 · Cited by 4 · see citing works
Small Molecules As pro-apoptotic Anticancer Agents
Seneci, P. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.41 · Cited by 4 · see citing works
Braña, I., Zamora, E., & Tabernero, J. M. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_15 · Cited by 3 · see citing works
Self-citationIn silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1
Kędzierski, J., Jäger, M.-C., Naeem, S., Odermatt, A., & Smieško, M. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116945 · Cited by 2 · see citing works
Chang, H. R. (2023) · Biomedicines · doi:10.3390/biomedicines11092527 · Cited by 2 · see citing works
Targeting Proteasomal Degradation of Soluble, Misfolded Proteins
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00003-5 · Cited by 2 · see citing works
Ubiquitin System-Driven Proteostasis in DNA Damage Response
Renata, K., Valerie, A. R., Qin, S., Kitty, I., Joshua, K. K., Seo, G., & Kim, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052356 · Cited by 1 · see citing works
Arrhythmias and QTc Prolongations
Locatelli, M., & Curigliano, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-44227-5.00013-2 · Cited by 1 · see citing works
Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy
Mattern, M. R., Eddins, M. J., Agarwal, S., Sterner, D. E., Kodrasov, M. P., Kumar, S., Wu, J., & Nicholson, B. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_12 · Cited by 1 · see citing works
Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
Dong, G., & Sheng, C. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_1 · Cited by 1 · see citing works
Hdm2 Small-Molecule Inhibitors For Therapeutic Intervention In B-Cell Lymphoma
Sosin, A. M. (2012) · Human Biology
Review Article A review of first-in-human small molecule oncology clinical trials
Greenwood, D. J. H., Stratford, I. J., & Booth, S. W. (2016)
Structural and Functional Characterization of the Human Mdm2 and MdmX RING Domains
Egorova, O. (2014) · YorkSpace (York University)
Kojima, K., & Andreeff, M. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch36
Gonzalez, N. S., García‐Álvarez, A., Braña, I., Tabernero, J. M., & Oristrell, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_14-1
Self-citationXu, N., Tong, Y., Ma, K., Jiang, L., & Zheng, W. (2025) · Medical Oncology · doi:10.1007/s12032-025-02912-0 · Cited by 1 · see citing works
Gu, H., Wang, S., Li, M., Guo, Y., Li, X., Gao, Z., Li, J., Liu, H., Zhou, X., & Xu, Y. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100124
- Authors
- Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., Knoblauch, R., & Zhuang, S. H.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Authors' Affiliations: 1Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona; 2Department of Hematology and Medical Oncology, Hospital Clinico, INCLIVA, University of Valencia, Valencia; 3Hospital Universitario 12 de Octubre, Madrid, Spain; 4Sint Augustinus, Antwerp; 5University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium; and 6Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
- Corresponding author
- Tabernero, Josep
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2011-10-01
- Volume
- 17
- Issue
- 19
- Pages
- 6313-6321
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2109295630
- Cited by
- 64
- References
- 11
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 6 · 2021: 2 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 8 · 2014: 11 · 2013: 6 · 2012: 7
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53 activation, pharmacokinetics, pharmacodynamics, advanced solid tumors, refractory cancer, maximum tolerated dose, dose-limiting toxicity, QTc prolongation, MIC-1, S phase arrest, apoptosis, dose escalation, breast cancer, safety and tolerability
- MeSH terms
- Administration, Oral, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Tryptamines, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
